HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Harold L. Lazar Gabriel S. Aldea Richard J. Shemin Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lazar, H. L. Articles by Shemin, R. J. Search for Related Content PubMed PubMed Citation Articles by Lazar, H. L. Articles by Shemin, R. J.

Ann Thorac Surg 1997;63:1701-1705
© 1997 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Heparin-Bonded Circuits Decrease Myocardial Ischemic Damage: An Experimental Study

Department of Cardiothoracic Surgery, The Boston University Medical Center, Boston, Massachusetts

Accepted for publication December 23, 1996.

Background. Heparin-bonded cardiopulmonary bypass circuits reduce complement activation, but their effect on myocardial function is unknown. This study was undertaken to determine whether heparin-bonded circuits reduce myocardial damage during acute surgical revascularization.

Methods. In 16 pigs, the second and third diagonal vessels were occluded with snares for 90 minutes followed by 45 minutes of cardioplegic arrest and 180 minutes of reperfusion with the snares released. During the period of coronary occlusion, all animals were placed on percutaneous bypass followed by standard cardiopulmonary bypass during the periods of cardioplegic arrest and reperfusion. In 8 pigs, heparin-bonded circuits were used, whereas 8 other pigs received nonbonded circuits.

Results. Animals treated with heparin-bonded circuits had the best preservation of wall motion scores (3.5 ± 0.3 versus 2.3 ± 0.2; 4 = normal to -1 = dyskinesis; p < 0.05), least tissue acidosis (change in pH = -0.31 ± 0.02 versus -0.64 ± 0.08; p < 0.05), smallest increase in lung H₂O (1.7% ± 0.7% versus 6.1% ± .5%; p < 0.05), and the lowest area of necrosis/area of risk (20.3% ± 2.2% versus 40.4% ± 1.6%; p < 0.05).

Conclusions. We conclude that heparin-bonded circuits significantly decrease myocardial ischemic damage during acute surgical revascularization.

This article has been cited by other articles:

				H. L. Lazar, P. M. Bokesch, F. van Lenta, C. Fitzgerald, C. Emmett, H. C. Marsh Jr, U. Ryan, and OBE and the TP10 Cardiac Surgery Study Group Soluble Human Complement Receptor 1 Limits Ischemic Damage in Cardiac Surgery Patients at High Risk Requiring Cardiopulmonary Bypass Circulation, September 14, 2004; 110(11_suppl_1): II-274 - II-279. [Abstract] [Full Text] [PDF]

				U. Demirkilic, E. Kuralay, H. Tatar, M. Kocakulak, C. Kocum, and H. Ayhan Investigation of Blood Compatibility and Determination of Clinical Performance of PMEA Coated and Flow Optimized Oxygenator Journal of Bioactive and Compatible Polymers, September 1, 2004; 19(5): 395 - 408. [Abstract] [PDF]

				T. Ikuta, H. Fujii, T. Shibata, K. Hattori, H. Hirai, H. Kumano, and S. Suehiro A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy Ann. Thorac. Surg., May 1, 2004; 77(5): 1678 - 1683. [Abstract] [Full Text] [PDF]

				H. I Flom-Halvorsen, E Ovrum, F Brosstad, G Tangen, M A. Ringdal, and R Oystese Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction Perfusion, September 1, 2002; 17(5): 339 - 345. [Abstract] [PDF]

				L.-C. Hsu Heparin-coated cardiopulmonary bypass circuits: current status Perfusion, September 1, 2001; 16(5): 417 - 428. [Abstract] [PDF]

				H. Suhara, Y. Sawa, M. Nishimura, H. Oshiyama, K. Yokoyama, N. Saito, and H. Matsuda Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model Ann. Thorac. Surg., May 1, 2001; 71(5): 1603 - 1608. [Abstract] [Full Text] [PDF]

				A. Belboul, C. Lofgren, C. Storm, and M. Jungbeck Heparin-coated circuits reduce occult myocardial damage during CPB: a randomized, single blind clinical trial Eur. J. Cardiothorac. Surg., May 1, 2000; 17(5): 580 - 586. [Abstract] [Full Text] [PDF]

				S. Wan, J.-L. LeClerc, M. Antoine, J.-M. DeSmet, A. P.C. Yim, and J.-L. Vincent Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study Ann. Thorac. Surg., October 1, 1999; 68(4): 1230 - 1235. [Abstract] [Full Text] [PDF]

				H. L. Lazar, Y. Bao, J. Gaudiani, S. Rivers, and H. Marsh Total Complement Inhibition : An Effective Strategy to Limit Ischemic Injury During Coronary Revascularization on Cardiopulmonary Bypass Circulation, September 28, 1999; 100(13): 1438 - 1442. [Abstract] [Full Text] [PDF]

				H. L. Lazar, C. Volpe, Y. Bao, S. Rivers, J. A. Vita, and J. F. Keaney Jr Beneficial effects of angiotensin-converting enzyme inhibitors during acute revascularization Ann. Thorac. Surg., August 1, 1998; 66(2): 487 - 492. [Abstract] [Full Text] [PDF]

				H. L. Lazar, T. Hamasaki, Y. Bao, S. Rivers, S. A. Bernard, and R. J. Shemin Soluble Complement Receptor Type I Limits Damage During Revascularization of Ischemic Myocardium Ann. Thorac. Surg., April 1, 1998; 65(4): 973 - 977. [Abstract] [Full Text] [PDF]